LEXEO Therapeutics is seeking a detail-oriented and proactive Procurement Specialist to support our growing clinical-stage gene therapy organization. This role will be instrumental in managing end-to-end procurement operations, ensuring that goods and services are sourced, documented, and delivered efficiently to meet the needs of our R&D and G&A teams. The ideal candidate will thrive in a dynamic, fast-paced biotech environment—balancing process discipline with flexibility—and will play a key role in strengthening Lexeo’s procurement infrastructure as we advance a cutting-edge pipeline addressing genetically defined cardiovascular and CNS diseases. This is an exciting opportunity to contribute to a mission-driven company pioneering transformative genetic medicines.
Primary Responsibilities
Manage end-to-end procurement activities
Execute and track purchase orders and change orders, ensuring accurate documentation and timely delivery
Coordinate with internal stakeholders including R&D and G&A to align procurement with project timelines and budgets
Maintain and update vendor records and procurement documentation in ERP (NetSuite) and procurement systems (Zip)
Ensure compliance with internal SOPs
Contribute to procurement process improvements
Required Skills and Qualifications
2–4 years of procurement or purchasing experience, preferably in the biotech, pharmaceutical, or life sciences industry
Understanding of procurement workflows and ERP systems (e.g., SAP, Oracle, NetSuite, or similar)
Excellent communication and relationship management skills
Attention to detail, with strong organizational and analytical abilities
Preferred Skills and Qualifications
Knowledge of supplier qualification processes and documentation standards in biotech
Certification in procurement or supply chain (e.g., CIPS, CPSM, APICS)
Experience supporting early-stage or growth-stage biotech companies
About Lexeo
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
